Close Menu

NEW YORK — BioPorto said on Wednesday that it has received CE marking for its point-of-care NGALds kidney injury test.

The Danish firm also said that its test for SARS-CoV-2 is currently under clinical testing at the University of California, Davis, with results due in early 2021.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.